2023
Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area
de Oliveira L, Dos Santos Barbosa M, Leite Torres A, Croda M, Oliveira da Silva B, Dos Santos P, Rossoni R, Machado L, Croda J, Maymone Gonçalves C, Marques M, da Silva Ferreira T, Sardi S, Campos G, de Almeida G, Alves Gomes M, Marchioro S, Simionatto S. Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area. PLOS ONE 2023, 18: e0295211. PMID: 38134187, PMCID: PMC10745159, DOI: 10.1371/journal.pone.0295211.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayCoronaVac inactivated vaccinesSARS-CoV-2SARS-CoV-2 infectionEnzyme-linked immunosorbent assay methodMedian ageSARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2Asymptomatic individualsRapid testSeropositivity rateBlood samplesEthnic groupsElevated seroprevalenceImmunosorbent assaySeroprevalence of SARS-CoV-2 infectionSARS-CoV-2 rapid testSeropositivityAntibodiesVulnerable ethnic groupsSeroprevalence
2022
SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020
Gouvea-Reis F, da Silva D, Borja L, de Oliveira Dias P, Percio J, Peterka C, de Oliveira J, Sodré G, Feres C, Dos Santos W, Souza F, Teixeira A, Cilião-Alves D, Romero G, Noronha E, Croda J, Haddad R, Ramalho W, de Moraes C, de Araújo W. SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020. International Journal Of Prisoner Health 2022, 19: 143-156. PMID: 38899623, DOI: 10.1108/ijph-08-2021-0083.Peer-Reviewed Original ResearchSARS-CoV-2 seroprevalenceOverall infection fatality rateInfection fatality rateChemiluminescence enzyme immunoassaySymptomatic individualsOverall SARS-CoV-2 seroprevalenceSARS-CoV-2 antibodiesDiagnostic accuracyAntibody rapid testLateral flow immunochromatographic assayCOVID-19 outbreakAsymptomatic infectionVaccination strategiesEligible individualsHigh seroprevalenceFatality ratePositive casesSeroprevalenceSerological assaysEnzyme immunoassayRapid testPriority groupsMass testingLFIA testRepresentative sample